The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
Stars using GLP-1 medications like Ozempic for dramatic weight loss are sparking talk of 'Ozempic face': sunken cheeks, new wrinkles, and sagging skin. Cleveland Clinic endocrinologist Vinni Makin notes this gaunt look stems from rapid fat loss. Public figures face scrutiny as the trend grows.
A new University of Oxford study reveals that GLP-1 users regain weight rapidly after stopping medications like Ozempic, with cardiometabolic benefits reversing within two years. This underscores the need for portion-controlled, nutrient-dense foods to maintain satiety on fewer calories. Food innovation will play a key role in supporting former users.
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
A woman called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain hospitalized her with pancreatitis linked to the drug. Now facing lifelong risks, she warns others to monitor symptoms closely.
Alisha Trafford called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain led to hospitalizations for pancreatitis and pancreatic necrosis, linked by doctors to the drug. She warns others to monitor symptoms closely.
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
Daily tasks like banking and food delivery are fully digital, yet healthcare remains outdated. In Nigeria, 47.7% of educated adults self-medicate antibiotics, driving antimicrobial resistance deaths. Digital platforms and GLP-1 weight loss programs offer seamless, compliant solutions.
Semaglutide-based Ozempic has become a weight loss sensation beyond diabetes treatment. Yet, over 1,800 US lawsuits signal serious risks including gastroparesis, bowel issues, and vision loss from NAION. UK and Irish prescribers face growing negligence exposure.
